Geron Positive Results from Phase 2 Study of Imetelstat

MENLO PARK, Calif., December 10, 2012 - Geron Corporation (GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company`s first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs). The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, by Prof. Dr. med. Gabriela M. Baerlocher of the University Hospital and University of Bern, Switzerland, and a principal investigator of the trial. To view the presentation slides, please visit www.geron.com/PDFs/Geron-Imetelstat-ETPh2-ASH-2012.pdf. .............................. ...............................................................................................................................................................................I sold most of my shares in Geron, will put most of the money in IBB and DVY. Geron is up 29% at $1.37. The results are good but it will take 2-3 years at least to bring to market, and the market for ET is small. Also I don't believe in Geron management. Plus I'm old and will be retiring soon, need income and stable share price. ........... ...............................................................................................................................................................................Good like in this rigged casino,